Xarelto® (rivaroxaban) – when the generic came out
| Region | FDA‑style approval | First commercial launch |
|--------|--------------------|--------------------------|
| United States | Approved as a generic in September 2017 | First generic product (Sandoz) hit the market in 2019 |
| Canada | Generic approval granted in 2019 | First generic available mid‑2020 |
| European Union | Generic approval began in 2020 | First generic marketed in 2021 |
| Other major markets (Australia, UK, etc.) | Approval dates vary (2021‑2023) | Availability typically 6–12 months after approval |
Bottom line: In the United States, the first generic version of Xarelto was approved in 2017 and became commercially available in 2019. Since then, several other manufacturers have entered the market, so generic rivaroxaban is now widely available and often significantly cheaper than the branded name.
---
A quick refresher on Xarelto (rivaroxaban)
- Class: Direct oral anticoagulant (DOAC) – it inhibits factor Xa in the coagulation cascade.
- Uses:
- Prevention of stroke and systemic embolism in non‑valvular atrial fibrillation.
- Treatment and secondary prevention of deep‑vein thrombosis (DVT) and pulmonary embolism (PE).
- Prevention of DVT/PE after hip/knee replacement surgery.
- Dosage: 5 mg, 10 mg, 15 mg, or 20 mg once daily, depending on the indication and patient factors.
- Key points for generics: The generic is chemically identical to the brand; it has the same dosage, efficacy, and safety profile. The only real difference is the price—generics are usually 20–30 % cheaper than Xarelto, and the savings can be even greater once the drug is fully in the generic market.
---
Why it matters
- Cost savings: In the U.S., the average wholesale price for Xarelto was about $500‑$600 per month before generics. Since generic launch, most patients can obtain rivaroxaban for roughly $200‑$250 per month, depending on insurance coverage and pharmacy discounts.
- Access: Generic availability increases formulary inclusion, especially for patients on high‑deductible plans or without prescription coverage.
- Insurance: Many insurers now place generic rivaroxaban at the first line of therapy, requiring prior authorization for the brand name.
---
How to get the generic
1. Check your insurance formulary – most plans list generic rivaroxaban (often under the brand “Rivaroxaban” or “Riva”).
2. Talk to your pharmacist – they can confirm the generic name (often “rivaroxaban” with the manufacturer’s label) and ensure the dosage matches your prescription.
3. Ask your prescriber – if your doctor has not already switched you to a generic, they can prescribe one directly.
If you’re currently taking Xarelto and wondering whether it’s worth switching, most patients do so without any change in medication effect, so it’s typically a straightforward, cost‑saving move.
---
Bottom line: Generic Xarelto (rivaroxaban) was approved in the U.S. in 2017 and began selling in 2019. Today it’s widely available, offers the same clinical benefits, and usually comes at a lower price.